Morphin Basi (Morphine Hydrochloride Trihydrate)

Morphine, the active ingredient in Morphin Basi, is an opioid analgesic presented as a sterile injectable for epidural, intramuscular and intrathecal use. It is employed to manage severe acute, postoperative, cancer‑related and chronic pain that requires opioid therapy.

GNH USA supplies Morphin Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Morphin Basi is an opioid analgesic that acts on the mu‑opioid receptor pathway to relieve intense pain. - Severe acute pain: provides rapid analgesia for patients experiencing intense short‑term pain. - Post‑operative pain: helps control pain after surgical procedures, facilitating recovery. - Cancer pain: offers sustained relief for malignant disease‑related discomfort. - Chronic pain requiring opioid therapy: used when other analgesics are insufficient for long‑term pain management.

Morphin Basi may cause a range of adverse reactions.

Common Side Effects: - Nausea: feeling of sickness often accompanied by vomiting. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or unsteadiness. - Sweating: excessive perspiration unrelated to temperature. - Itching: mild skin pruritus, especially at the injection site.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure leading to faintness. - Anaphylactic reaction: sudden, severe allergic response with rash, swelling, and airway compromise. - Adrenal insufficiency: impaired cortisol production causing fatigue and weakness.

When using Morphin Basi, clinicians should observe several safety measures. - Pain assessment: evaluate severity and type of pain before initiating therapy. - Respiratory monitoring: regularly check breathing rate and oxygen saturation, especially after dose adjustments. - Opioid tolerance: assess patient’s prior exposure to opioids to avoid overdose. - Concomitant CNS depressants: avoid or carefully titrate when combined with benzodiazepines or alcohol. - Renal/hepatic impairment: consider dose reduction in patients with organ dysfunction. - Store at ambient temperature: keep in original container, protect from moisture and light.

Morphin Basi can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other opioids: additive respiratory depression and sedation. - Central nervous system depressants (e.g., benzodiazepines): increased risk of profound sedation. - Monoamine oxidase inhibitors: potential for severe serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise morphine plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect. - Diuretics: can enhance hypotensive response.